NCT03262610View on ClinicalTrials.gov

Setmelanotide in a Single Patient With Partial Lipodystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
HypertriglyceridemiaObesity
Interventions
DRUG

Setmelanotide

daily subcutaneous injection

Trial Locations (1)

48105

University of Michigan, Ann Arbor

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT03262610 - Setmelanotide in a Single Patient With Partial Lipodystrophy | Biotech Hunter | Biotech Hunter